Legacy Pharma Inc. SEZC Announces the Acquisition of InterMune, Inc. and the U.S. Rights to Esbriet® from Genentech a Member of the Roche Group – PR.com

George
Town,
Cayman
Islands,
February
06,
2025
–(PR.com)– Legacy
Pharma
Inc.
SEZC
(“Legacy
Pharma”
or
the
“Company”),
a
specialty
pharmaceutical
company,
announced
the
completion
of
the
acquisition
of
InterMune,
Inc.
(“InterMune”)
and
the
intellectual
property
rights
to
Esbriet®
(pirfenidone)
in
the
United
States
from
Genentech,
​a
member
of
the
Roche
Group​.
This
strategic
acquisition
underscores
Legacy
Pharma’s
commitment
to
expanding
its
portfolio
of
high-quality
pharmaceutical
products
and
enhancing
patient
access
to
innovative
treatments.

Esbriet®,
a
medication
used
to
treat
idiopathic
pulmonary
fibrosis
(IPF),
has
shown
significant
promise
in
improving
the
lives
of
patients
with
this
chronic
and
life-threatening
lung
disease.
With
this
acquisition,
Legacy
Pharma
aims
to
ensure
the
continued
availability
and
distribution
of
Esbriet®
to
patients​
​across
the
United
States.​
Genentech
will
continue
to
provide
access
to
Esbriet®
in
the
United
States
until
the
completion
of
the
business
transfer.
Furthermore,
Roche
will
retain
commercial
rights
in
all
other
territories.​

“We
are
excited
to
acquire
InterMune
and
add
Esbriet®
to
our
portfolio
of
essential
medications,”
said
Mark
Thompson,
CEO
of
Legacy
Pharma.
“This
acquisition
aligns
with
our
mission
to
provide
patients
with
access
to
innovative
and
life-changing
treatments.​​​​”

Legacy
Pharma
Inc.
SEZC
is
dedicated
to
maintaining
the
highest
standards
of
quality
and
customer
service.
The
Company’s
acquisition
of
InterMune
and
​​​certain​​
​U.S.
intellectual
property
rights
to
Esbriet®
is
a
testament
to
its
ongoing
commitment
to
expanding
its
portfolio
of
legacy
pharmaceutical
products
and
strengthening
its
collaboration
with
key
partners
in
the
industry,
such
as
​Genentech​.

​​​About
Legacy
Pharma
Inc.
SEZC​​​
​​​

Legacy
Pharma
Inc.
SEZC
is
a
pharmaceutical
company
focused
on
distributing
established
prescription
pharmaceutical
products.
The
Company
is
committed
to
ensuring
that
in-demand
brands
remain
available
for
distribution
to
patients
who
need
them.
For
more
information
about
Legacy
Pharma
Inc.
SEZC
and
its
product
offerings,
please
visit

www.legacypharmainc.com.

​​For
further
information​,
contact:

contact@legacypharmainc.com